The 21st Century Cures Act: Allowing The FDA To Address Modern Value Communication Needs
How to prove the real – and implicit – economic value of pharma products to payers and other stakeholders while FDA regulatory approvals adhere to a historically rigid standard of proof based on randomized tests against placebo in a controlled patient population? The 21st Century Cures Act may finally be extending a new path forward that offers legislative endorsement for use of a greater variety of evidence. What the FDA decides to do on this score is emerging as a key issue for biopharma in 2017.
You may also be interested in...
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.
Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.